Urso 250 and Hyperammonaemia - a phase IV clinical study of FDA data

Summary:

Hyperammonaemia is reported as a side effect among people who take Urso 250 (ursodiol), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Nexavar, and have Hepatic neoplasm malignant.

The phase IV clinical study analyzes which people have Hyperammonaemia when taking Urso 250. It is created by eHealthMe based on reports of 5,057 people who have side effects when taking Urso 250 from the FDA, and is updated regularly.

What is Urso 250?

Urso 250 has active ingredients of ursodiol. eHealthMe is studying from 5,080 Urso 250 users. Check the latest studies of Urso 250.

What is Hyperammonaemia?

Hyperammonaemia is found to be associated with 397 drugs and 562 conditions by eHealthMe. Check the latest studies of Hyperammonaemia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

5,057 people reported to have side effects when taking Urso 250.
Among them, 42 people (0.83%) have Hyperammonaemia.

Among these 42 people:

How long have people been on Urso 250 when they have Hyperammonaemia? *

What is the gender of people who have Hyperammonaemia when taking Urso 250? *

female: 28.57 %
male: 71.43 %

What is the age of people who have Hyperammonaemia when taking Urso 250? *

What are other drugs people take besides Urso 250? *

What are other side effects people have besides Hyperammonaemia? *

Hepatic Function Abnormal: 15 people, 35.71%
Hepatic Failure (liver failure): 12 people, 28.57%
Hepatic Encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure): 10 people, 23.81%
Ascites (accumulation of fluid in the abdominal cavity): 8 people, 19.05%
Hepatic Neoplasm Malignant (liver cancer): 8 people, 19.05%
Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood): 7 people, 16.67%
Blood Amylase Increased: 6 people, 14.29%
Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood): 5 people, 11.90%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 5 people, 11.90%
Fever: 5 people, 11.90%

What are the existing conditions these people have? *

Hepatic Neoplasm Malignant (liver cancer): 29 people, 69.05%
Ascites (accumulation of fluid in the abdominal cavity): 8 people, 19.05%
Oedema (fluid collection in tissue): 7 people, 16.67%
Insomnia (sleeplessness): 7 people, 16.67%
Diabetes: 7 people, 16.67%
Metastatic Pain (pain due to cancer spread): 5 people, 11.90%
Constipation: 5 people, 11.90%
Enlarged Prostate: 5 people, 11.90%
High Blood Pressure: 5 people, 11.90%
Acarodermatitis (skin inflammation caused by mites (acarids)): 4 people, 9.52%

* Approximation only. Some reports may have incomplete information.

Do you take Urso 250 and have Hyperammonaemia?

- Check whether Hyperammonaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Urso 250:

Urso 250 (5,080 reports)

Hyperammonaemia treatments and more:

Hyperammonaemia (6,053 reports)

Browse all side effects of Urso 250:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperammonaemia:

Hyperammonaemia (397 drugs)

Browse all the conditions that are associated with Hyperammonaemia:

Hyperammonaemia (562 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ursodiol (the active ingredients of Urso 250) and Urso 250 (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.